MTG2 Antibody

What is MTG2 protein and what are its primary cellular functions?

MTG2 is a GTP-binding protein that plays a crucial role in the ribosome maturation process . It functions primarily in transcriptional regulation and is involved in multiple cellular processes including apoptosis. According to UniProt functional data, MTG2 (GTPBP5) specifically participates in the assembly and maturation of ribosomes, which are essential for protein synthesis . Dysregulation of MTG2 has been linked to various disease states, particularly cancer and certain developmental disorders, making it an important target for research in molecular biology and oncology .

What applications are MTG2 antibodies validated for in research settings?

MTG2 antibodies, such as the polyclonal antibody PACO03818, have been validated for several research applications:

The antibody shows high specificity for human MTG2 protein and has been utilized successfully in detecting and analyzing MTG2 expression in various cell types . This makes it particularly valuable for investigations in fields such as cancer research and molecular biology where understanding protein expression patterns is critical.

What species reactivity does the MTG2 antibody demonstrate?

The MTG2 polyclonal antibody (PACO03818) exhibits reactivity against multiple species, specifically:

• Human

• Mouse

• Rat

This cross-species reactivity makes the antibody versatile for comparative studies across these mammalian models . The antibody was developed using a synthesized peptide derived from the internal region of human GTPBP5, which shares significant homology with mouse and rat orthologs, explaining its cross-reactivity.

How should researchers optimize immunohistochemistry protocols for MTG2 antibody?

When optimizing immunohistochemistry protocols with MTG2 antibody, researchers should consider:

• Dilution optimization: Start with the recommended dilution range of 1:100-1:300 for IHC applications . Perform a dilution series to determine the optimal concentration for your specific tissue.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally effective for MTG2 antibody.

• Blocking conditions: Use 5% BSA in PBS or 5-10% normal serum from the same species as the secondary antibody to reduce background.

• Incubation conditions: Primary antibody incubation is typically performed overnight at 4°C, but this should be optimized.

• Detection system: An HRP-DAB system works well with this antibody, but fluorescent secondary antibodies can also be used for co-localization studies.

For maximum reproducibility, always include positive controls (tissues known to express MTG2) and negative controls (primary antibody omitted or isotype control).

What are the recommended sample preparation techniques for Western blotting with MTG2 antibody?

For optimal Western blotting results with MTG2 antibody:

• Protein extraction: Use RIPA buffer supplemented with protease inhibitors to extract total protein from tissues or cell cultures.

• Protein quantification: Perform BCA or Bradford assay to ensure equal loading across samples.

• Sample preparation: Mix protein lysates with Laemmli buffer containing DTT or β-mercaptoethanol and heat at 95°C for 5 minutes.

• Gel electrophoresis: Load 20-40 μg of protein per well on a 10-12% SDS-PAGE gel.

• Transfer conditions: Transfer to PVDF or nitrocellulose membrane at 100V for 60-90 minutes or at 30V overnight at 4°C.

• Blocking: Block with 5% non-fat dry milk or 5% BSA in TBST for 1 hour at room temperature.

• Antibody incubation: Dilute MTG2 antibody in blocking buffer (1:500-1:2000) and incubate overnight at 4°C.

• Detection: Use appropriate HRP-conjugated secondary antibody and ECL detection system.

The predicted molecular weight of MTG2/GTPBP5 is approximately 68 kDa, which should be verified during analysis .

What controls should be included when performing experiments with MTG2 antibody?

The inclusion of proper controls is crucial for reliable interpretation of results with MTG2 antibody:

For more rigorous validation, particularly in novel applications, consider using siRNA knockdown or knockout samples as additional specificity controls.

How can MTG2 antibody be utilized to study ribosome maturation processes?

MTG2 is directly involved in ribosome maturation processes , making its antibody a valuable tool for studying these mechanisms:

• Co-immunoprecipitation (Co-IP): Use MTG2 antibody to pull down protein complexes involved in ribosome assembly. This can identify interaction partners critical for ribosome maturation.

• Immunofluorescence co-localization: Perform dual staining with MTG2 antibody and markers of nucleolar compartments (fibrillarin, nucleolin) to visualize the spatial distribution of MTG2 during ribosome biogenesis.

• Proximity ligation assay (PLA): Combine MTG2 antibody with antibodies against known ribosomal proteins to detect and quantify protein-protein interactions that occur during ribosome assembly.

• Chromatin immunoprecipitation (ChIP): For investigating potential roles of MTG2 in transcriptional regulation of ribosomal RNA genes.

• Pulse-chase experiments: Combine MTG2 antibody detection with labeled ribosomal components to track ribosome assembly kinetics.

Since MTG2 is a GTP-binding protein involved in maturation processes, researchers can use these approaches to elucidate the specific steps in ribosome biogenesis where MTG2 functions and how its dysregulation might impact protein synthesis in disease states.

What strategies can be employed to study MTG2 expression in cancer research?

Given the links between MTG2 dysregulation and cancer , several research strategies can be employed:

• Tissue microarray (TMA) analysis: Use MTG2 antibody on TMAs containing multiple cancer types to assess expression patterns across different malignancies.

• Correlation with clinical parameters: Compare MTG2 expression levels (determined by IHC or Western blotting) with patient survival, tumor grade, and response to therapy.

• Cancer cell line panels: Screen diverse cancer cell lines for MTG2 expression to identify cancer types with aberrant expression.

• Expression modulation studies: Use siRNA knockdown or CRISPR-Cas9 knockout of MTG2 in cancer cell lines to assess effects on:

  • Proliferation rates

  • Migration and invasion capacity

  • Apoptosis resistance

  • Sensitivity to chemotherapeutic agents

• Xenograft models: Compare tumors with normal vs. altered MTG2 expression in vivo to evaluate impacts on tumor growth and metastasis.

These approaches can help elucidate the potential role of MTG2 in cancer pathogenesis and its value as a biomarker or therapeutic target.

How can MTG2 antibody be incorporated into multi-parameter analysis techniques?

For comprehensive understanding of MTG2 function in complex biological systems:

• Multiplex immunofluorescence: Combine MTG2 antibody with antibodies against other proteins of interest for co-expression analysis. This allows simultaneous detection of multiple proteins within the same sample.

• Mass cytometry (CyTOF): MTG2 antibody can be metal-conjugated for use in high-dimensional single-cell analysis.

• Single-cell Western blotting: Apply MTG2 antibody in microfluidic platforms to analyze protein expression at the single-cell level.

• Imaging mass spectrometry: Combine with MTG2 immunostaining for spatial proteomics.

• Sequential immunostaining: Use cyclic immunofluorescence approaches where MTG2 antibody is part of a panel of 30+ antibodies applied sequentially to the same sample.

These advanced techniques overcome the limitations of conventional single-parameter analyses and provide a more comprehensive view of MTG2's role in cellular processes.

What are common issues encountered with MTG2 antibody in IHC and how can they be resolved?

Researchers may face several challenges when using MTG2 antibody for immunohistochemistry:

For MTG2 antibody specifically, the recommended dilution range for IHC is 1:100-1:300 . If optimal results are not achieved within this range, consider testing broader dilutions and altering incubation conditions.

How can researchers assess and ensure the quality of MTG2 antibody over time?

To maintain antibody quality and reliability:

• Aliquoting strategy: Upon receipt, divide the antibody into small single-use aliquots to minimize freeze-thaw cycles.

• Storage conditions: Store at -20°C in 50% glycerol buffer containing 0.5% BSA and 0.02% sodium azide as specified for the MTG2 antibody (PACO03818) .

• Positive control tracking: Regularly test the antibody on a consistent positive control sample to monitor performance over time.

• Reference standards: Maintain images of optimal staining patterns as references for comparison.

• Lot testing: When receiving a new lot, perform side-by-side comparisons with the previous lot to ensure consistent performance.

• Record keeping: Document all usage, including dates, applications, and observations about performance to track potential degradation.

Proper storage in the recommended buffer (PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide for MTG2 antibody) is crucial for maintaining antibody activity.

How should MTG2 expression data be quantified and analyzed in different experimental contexts?

Appropriate quantification methods depend on the experimental approach:

• Western blot quantification:

  • Use densitometry to measure band intensity

  • Normalize to loading controls (β-actin, GAPDH)

  • Express results as relative intensity compared to control samples

  • Use at least three biological replicates for statistical validity

• IHC quantification methods:

  • H-score: Combines intensity (0-3) and percentage of positive cells

  • Allred score: Sum of proportion score (0-5) and intensity score (0-3)

  • Digital image analysis: Automated quantification of staining intensity and distribution

• Immunofluorescence quantification:

  • Mean fluorescence intensity (MFI) measurements

  • Co-localization coefficients (Pearson's, Manders') for co-expression studies

  • Subcellular distribution analysis

• Statistical approaches:

  • For normally distributed data: t-tests, ANOVA with appropriate post-hoc tests

  • For non-parametric data: Mann-Whitney U test, Kruskal-Wallis test

  • Correlation with clinical parameters: Spearman or Pearson correlation coefficients

  • Survival analysis: Kaplan-Meier curves with log-rank tests

When reporting MTG2 expression analysis, always include detailed methods describing antibody dilution, incubation conditions, detection systems, and quantification parameters to ensure reproducibility.

How can researchers interpret MTG2 staining patterns in relation to its biological function?

The interpretation of MTG2 staining patterns should consider:

• Subcellular localization:

  • Nuclear/nucleolar localization: Consistent with role in ribosome maturation

  • Cytoplasmic localization: May indicate transport of mature ribosomes or alternative functions

  • Altered localization in disease states: May suggest dysfunction

• Expression intensity:

  • Relative expression levels between normal and pathological tissues

  • Correlation with clinical parameters in disease studies

  • Changes in expression during cellular processes (differentiation, stress response)

• Heterogeneity of expression:

  • Variation across different cell types within a tissue

  • Clonal variation within tumors

  • Changes at different disease stages

• Co-expression patterns:

  • Relationship with other ribosome biogenesis factors

  • Correlation with proliferation markers

  • Association with stress response proteins

Since MTG2 is involved in ribosome maturation , its expression is expected to correlate with cellular processes requiring active protein synthesis, such as proliferation and growth. Altered expression patterns may indicate dysregulation of these fundamental cellular processes.